🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

90 results for “doxorubicin” Clear

  1. RITUXIMAB, CYCLOPHOSPHAMIDE , AZD0486, PREDNISOLONE , VINCRISTINE , Calquence 100 mg film-coated tablets, RITUXIMAB , AZD0486, DOXORUBICIN , Calquence 100 mg film-coated tablets, PREDNISONE , AZD0486, AZD0486

    AstraZeneca AB

    Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  2. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  3. SILTUXIMAB , PREDNISOLONE , CYCLOPHOSPHAMIDE , CARBOPLATIN , PARACETAMOL , ETOPOSIDE , VINCRISTINE , LENALIDOMIDE , DIPHENHYDRAMINE , GEMCITABINE , PREDNISONE , OXALIPLATIN , TOCILIZUMAB , Epcoritamab, Epcoritamab, DEXAMETHASONE , DOXORUBICIN , CYTARABINE , RITUXIMAB , IFOSFAMIDE , ANAKINRA , BENDAMUSTINE

    Genmab A/S

    Lymphoma of B-cell origin

    phase 2 small molecule active

    1 trial

  4. Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin

    Bayer HealthCare AG

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

  5. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  6. VENETOCLAX , Epcoritamab, Epcoritamab, VINCRISTINE , Jaypirca 100 mg film-coated tablets, DOXORUBICIN , Jaypirca 50 mg film-coated tablets, CYCLOPHOSPHAMIDE , PREDNISOLONE , LENALIDOMIDE , RITUXIMAB

    Genmab A/S

    Chronic Lymphocytic Leukemia

    phase 2 small molecule active

    1 trial

  7. VINCRISTINE , MELPHALAN , DOXORUBICIN , CYCLOPHOSPHAMIDE , IFOSFAMIDE , Trecondi 1 g powder for solution for infusion, ETOPOSIDE , Trecondi 5 g powder for solution for infusion

    Fondazione Telethon ETS

    Ewing Sarcoma

    phase 2 small molecule active

    1 trial

  8. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  9. doxorubicin, docetaxel

    Hospital Authority, Hong Kong

    Metastatic Breast Cancer

    phase 2 small molecule completed

    1 trial

  10. A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

    Hoffmann-La Roche

    Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), Epstein-Barr virus−positive DLBCL

    phase 1 other active

    1 trial

  11. Doxorubicin

    United Therapeutics Europe Ltd

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  12. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  13. ZIO-201-T and doxorubicin

    Alaunos Therapeutics

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  14. Doxorubicin Accord 2 mg/ml koncentrat till infusionsvätska, lösning, Paclitaxel Accord 6 mg/ml koncentrat till infusionsvätska, lösning, Docetaxel Ebewe 10 mg/ml koncentrat till infusionsvätska, lösning, Epirubicin Accord 2 mg/ml injektions-/infusionsvätska, lösning, Sendoxan pulver till injektionsvätska, lösning

    The George Institute

    Breast cancer female NOS

    approved small molecule active

    1 trial

  15. PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    approved small molecule active

    1 trial

  16. Pegylated liposomal doxorubicin

    The First People's Hospital of Lianyungang

    Breast Cancer

    approved small molecule active

    1 trial

  17. Liposomal Doxorubicin

    United Therapeutics Europe Ltd

    Ovarian Cancer

    small molecule terminated

    1 trial

  18. Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar

    The University of Hong Kong

    Recurrent Ovarian Carcinoma

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources